Prediction of renal end points in chronic kidney disease

Kidney International

Volumn 83, Issue 2, 2013, Pages 189-191

  Al Aly, Ziyad ^a  

^a VA St Louis Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1;

ACCURACY; ALBUMINURIA; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SYNDROME DELINEATION;

EID: 84873363357     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.418     Document Type: Note

References (10)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047.
2. Al-Aly Z, Zeringue A, Fu J et al. Rate of kidney function decline associates with mortality. J Am Soc Nephrol 2010; 21: 1961-1969.
3. Taal MW, Brenner BM. Renal risk scores: progress and prospects. Kidney Int 2008; 73: 1216-1219.
4. Johnson ES, Thorp ML, Platt RW et al. Predicting the risk of dialysis and transplant among patients with CKD: a retrospective cohort study. Am J Kidney Dis 2008; 52: 653-660.
5. Tangri N, Stevens LA, Griffith J et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011; 305: 1553-1559.
6. Jardine MJ, Hata J, Woodward M et al. Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis 2012; 60: 770-778.
7. Wong MG, Perkovic V, Woodward M et al. Circulating bone morphogenetic protein-7 and transforming growth factor-b1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int 2012; 83: 278-284.
8. O'Hare AM, Bertenthal D, Covinsky KE et al. Mortality risk stratification in chronic kidney disease: one size for all ages? J Am Soc Nephrol 2006; 17: 846-853.
9. Gatault P, Al-Najjar A, Barbet C et al. Doubling of serum creatinine in clinical trials, cost-effectiveness studies, and individual patients: adequate use in renal transplantation. Transplantation 2011; 92: 1012-1017.
10. Lambers Heerspink HJ, Perkovic V, de Zeeuw D. Is doubling of serum creatinine a valid clinical 'hard' endpoint in clinical nephrology trials? Nephron Clin Pract 2011; 119: c195-c199discussion c199.